Skip to main content

Table 2 Overview of main results of integrated models

From: Integrated care of severe infectious diseases to people with substance use disorders; a systematic review

Group Author/year of publication Disease Study design Number of individuals Loss-to-follow-up (%) Main results
Interventions with opioid agonist treatment Achmad, Y.M. et al (2009) HIV Cohort 223 No difference between the intervention group and the control group. No data are available. Virological response (HIV viral load): IG: 97 % versus CG: 90 %, p = 0.27
Immunological response (CD4 cell count): IG: 69 % versus CG: 57 %, p = 0.93.
Batki, S.L. et al (2002) TB RCT 111 52% TBC completion (≥ 80 % of the doses administrated): 59.5 % in Standard Methadone Treatment, 77.1 % in Minimal Methadone Treatment and 13.1 % in Routine Care, p < 0.01.
Bruce, D.R. et al (2012) HCV RCT 21 67% SVR: Six of ten in the intervention group and one of four in the control group, achieved SVR
Lucas, G.M. et al (2010) HIV RCT 93 17% HIV RNA and CD4 cell count: No significant differences between opioid agonist therapy in the clinic-based buprenorphine strategy versus specialized opioid treatment program were found (p = 0.31 and p = 0.16, respectively)
Morozova, O. et al (2013) TB Cohort 110 18 % Treatment completion: IG: 90 % versus CG: 74 %, p = 0.03.
Tetrault, J.M. et al (2012) HIV RCT 47 30% Virological response (HIV viral load): Descreased from 58 % at baseline to 43 % at 12 weeks in IG, and from 56 % to 35 % in CG, p = 0.84 and p = 0.27, respectively.
Interventions without opioid agonist treatment Groessl, E.J. et al (2017) HCV RCT 79 37% SVR: 67 % in IG versus 55 % in CG, p = 0.23.
Ho, S.B. et al (2015) HCV RCT 363 53% SVR: 16 % and 8 % in IG and in CG, respectively, achieved SVR. OR 2.26 (95 % CI: 1.15-4.44, p = 0.02)
SVR (active substance users and alcohol dependents): IG: 11 % versus CG: 7 %, p = 0.49.
Sánchez, G.C. et al (2012) HIV Cohort 119 In IG 13 % versus in CG 8 % permanently discontinued treatment. Virological response (HIV RNA load < 50 copies/mL) at week 48: 93 % (95 % CI = 87 % - 99 %) in IG versus 94 % (95% CI = 84 % - 100 %) in CG.
Virological response (HIV RNA load < 50 copies/mL) at week 96: 87 % (95 % CI = 79 % - 95 %) in IG, and 88 % (95% CI = 78 % - 97 %) in CG.
No significant differences were found, Kaplan-Meier estimates, log rank test, p =0.965.
Simoni, J.M. et al (2007) HIV RCT 136 All recruited were followed up, but only 59 % at baseline, 65 % at three months, and 61 % at six months reported adherence on 95 % or more. HIV RNA: HIV suppression was not found significantly different between the integrated group and the control group at baseline, three months and six months follow up.
  1. Abbreviations: CG Control group, HCV Hepatitis C virus, HIV Human immunodeficiency virus, IG Intervention group, RCT Randomized controlled trial, SD Standard deviation, SUD Substance use disorder, SVR Sustained virological response, TB Mycobactrium tuberculosis